Seo Suk Bae, Wan Jovian, Hidajat Inneke Jane, Tanojo Henry, Pranata Achmad Yudha, Yi Kyu-Ho
SeoAhSong Dermatologic Clinic, Seoul, Korea.
Medical Research, Inc., Wonju, Korea.
Dermatol Surg. 2025 May 1;51(5):505-508. doi: 10.1097/DSS.0000000000004533. Epub 2024 Dec 19.
Melasma, a common skin hyperpigmentation disorder, has traditionally been linked to hormonal changes in genetically predisposed individuals. Recent studies, however, highlight the role of photoageing, particularly from visible light exposure, as a significant contributing factor. Effective treatments for melasma and associated signs of photoageing remain a clinical challenge.
This study aimed to evaluate the efficacy and safety of Poly-d,l-lactic acid (PDLLA) delivered via laser-induced microjet injectors in treating melasma and signs of photoageing.
Eighteen Korean participants aged 42 to 74, with Fitzpatrick skin types III to IV, were enrolled. All participants exhibited melasma, signs of photoageing, or both. PDLLA was administered using the Mirajet device over 5 to 9 sessions. Clinical outcomes were assessed using the modified Melasma Area and Severity Index (MASI) and the Glogau Classification for photoageing. Adverse events were monitored throughout the study.
Significant improvements were observed in both melasma severity and signs of photoageing. The mean MASI score decreased from 22.72 to 7.31 ( p =.004). Photoageing severity, as assessed by the Glogau Classification, also improved notably. Minimal side effects were reported, primarily transient bleeding.
PDLLA administered via laser-induced microjet injectors appears to be a safe and effective treatment for melasma and photoageing, particularly in patients with more severe melasma. These findings suggest the potential for PDLLA in skin rejuvenation; however, further randomised controlled trials are warranted to confirm these results and optimise treatment protocols.
黄褐斑是一种常见的皮肤色素沉着过度疾病，传统上一直被认为与遗传易感性个体的激素变化有关。然而，最近的研究强调了光老化的作用，特别是可见光暴露，是一个重要的促成因素。黄褐斑及相关光老化迹象的有效治疗仍然是一项临床挑战。
本研究旨在评估通过激光诱导微喷射注射器给药的聚-d，l-乳酸（PDLLA）治疗黄褐斑和光老化迹象的疗效和安全性。
招募了18名年龄在42至74岁之间、皮肤类型为菲茨帕特里克III至IV型的韩国参与者。所有参与者均表现出黄褐斑、光老化迹象或两者皆有。使用Mirajet设备分5至9次给予PDLLA。使用改良的黄褐斑面积和严重程度指数（MASI）和光老化的Glogau分类评估临床结果。在整个研究过程中监测不良事件。
黄褐斑严重程度和光老化迹象均有显著改善。平均MASI评分从22.72降至7.31（p = 0.004）。通过Glogau分类评估的光老化严重程度也有明显改善。报告的副作用最小，主要是短暂出血。
通过激光诱导微喷射注射器给药的PDLLA似乎是治疗黄褐斑和光老化的安全有效方法，特别是对于黄褐斑较严重的患者。这些发现表明PDLLA在皮肤年轻化方面具有潜力；然而，需要进一步的随机对照试验来证实这些结果并优化治疗方案。
